The worldwide impact of the seven-valent pneumococcal conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 31, Issue 5, 2012, Pages 501-508

  Fitzwater, Sean P ^a   Chandran, Aruna ^a   Santosham, Mathuram ^a   Johnson, Hope L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Impact; Invasive pneumococcal disease; Pneumococcal conjugated vaccine; Pneumococcal pneumonia; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ARTICLE; CHILDHOOD MORTALITY; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; GAMBIA; HERD IMMUNITY; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INCIDENCE; LOWEST INCOME GROUP; OUTPATIENT DEPARTMENT; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; SOUTH AFRICA; STAPHYLOCOCCAL BACTEREMIA; STREPTOCOCCUS PNEUMONIA;

ADOLESCENT; ADULT; CHILD; CHILD MORTALITY; CHILD, PRESCHOOL; GAMBIA; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; WORLD HEALTH; YOUNG ADULT;

EID: 84860234046     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824de9f6     Document Type: Article

References (69)

1. O'Brien KL, Wolfson LJ, Watt JP, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
2. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under fi ve: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348.
3. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med. 2009;30:189-209.
4. Hendley JO, Sande MA, Stewart PM, et al. Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis. 1975;132:55-61.
5. American Academy of Pediatric Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451-1465.
6. McIntosh ED. Treatment and prevention strategies to combat pediatric pneumococcal meningitis. Expert Rev Anti Infect Ther. 2005;3:739-750.
7. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. In: Atkinson W, Hamborsky J, McIntyre L, et al, eds. 10th ed. Washington, DC: Public Health Foundation; 2008.
8. Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J. 2000;19:388-393.
9. Schuerman L, Borys D, Hoet B, et al. Prevention of otitis media: now a reality? Vaccine. 2009;27:5748-5754.
10. Rodgers GL, Klugman KP. The future of pneumococcal disease prevention. Vaccine. 2011;29 (suppl 3):C43-C48.
11. Black S, Shinefi eld H. Safety and effi cacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr. 2002;161 (suppl 2):S127-S131.
12. O'Brien KL, Moulton LH, Reid R, et al. Effi cacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361.
13. Klugman KP, Madhi SA, Huebner RE, et al.; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
14. Cutts FT, Zaman SM, Enwere G, et al.; Gambian Pneumococcal Vaccine Trial Group. Effi cacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139-1146.
15. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defi ned pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;4:CD004977.
16. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
17. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than fi ve years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
18. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med. 2004;10:811-813.
19. Eskola J, Kilpi T, Palmu A, et al.; Finnish Otitis Media Study Group. Effi cacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
20. Black S, Shinefield H, Fireman B, et al. Effi cacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
21. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22:10-16.
22. Kilpi T, Ahman H, Jokinen J, et al.; Finnish Otitis Media Study Group. Protective effi cacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis. 2003;37:1155-1164.
23. Cheung YB, Zaman SM, Nsekpong ED, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J. 2009;28:990-995.
24. Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis. 2002;185:927-936.
25. Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999;180:1171-1176.
26. Obaro SK, Adegbola RA, Chang I, et al. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J. 2000;19:463-469.
27. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196:1211-1220.
28. Dagan R, Muallem M, Melamed R, et al. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J. 1997;16:1060-1064.
29. International Vaccine Access Center.Vaccine Information Management System. Baltimore, MD: International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health. Database accessed June 30, 2011.
30. Foster D, Walker AS, Paul J, et al.; Oxford Invasive Pneumococcal Surveillance Group. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2011;60(Pt 1):91-97.
31. Hanquet G, Lernout T, Vergison A, et al.; Belgian IPD Scientifi c Committee. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. 2011;29:2856-2864.
32. Harboe ZB, Valentiner-Branth P, Benfi eld TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine. 2010;28:2642-2647.
33. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760-768.
34. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
35. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26:3277-3281.
36. Williams SR, Mernagh PJ, Lee MH, et al. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust. 2011;194:116-120.
37. Kellner JD, Vanderkooi OG, MacDonald J, et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. 2009;49:205-212.
38. Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine. 2005;23:5464-5473.
39. Rückinger S, van der Linden M, Reinert RR, et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27:4136-4141.
40. Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and infl uenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e00309-e00310.
41. Strategic Advisory Group of Experts on Immunization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011-conclusions and recommendations. Wkly Epidemiol Rec. 2012;87:1-16.
42. Zangeneh TT, Baracco G, Al-Tawfi q JA. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Expert Rev Vaccines. 2011;10:345-353.
43. Carvalho Mda G, Pimenta FC, Gertz RE Jr, et al.; Active Bacterial Core Surveillance Team. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol. 2009;47:554-559.
44. Park IH, Moore MR, Treanor JJ, et al.; Active Bacterial Core Surveillance Team. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis. 2008;198:1818-1822.
45. Black S. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr Infect Dis J. 2010;29:301-303.
46. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28:4249-4259.
47. De Wals P, Robin E, Fortin E, et al. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J. 2008;27:963-968.
48. Durando P, Crovari P, Ansaldi F, et al.; Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the fi ve-year experience of Liguria Region, Italy. Vaccine. 2009;27:3459-3462.
49. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
50. Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J. 2010;29:607-612.
51. Lee GE, Lorch SA, Sheffl er-Collins S, et al. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126:204-213.
52. Patrzalek M, Albrecht P, Sobczynski M. Signifi cant decline in pneumonia admission rate after the introduction of routine 2 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis. 2010;29:787-792.
53. Pírez MC, Algorta G, Cedrés A, et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J. 2011;30:669-674.
54. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161:1162-1168.
55. Grijalva CG. Recognising pneumonia burden through prevention. Vaccine. 2009;27 Suppl 3:C6-C8.
56. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118:865-873.
57. Kronman MP, Hersh AL, Feng R, et al. Ambulatory visit rates and antibiotic prescribing for children with pneumonia, 1994-2007. Pediatrics. 2011;127:411-418.
58. Stamboulidis K, Chatzaki D, Poulakou G, et al. The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J. 2011;30:551-555.
59. Wals PD, Carbon M, Sévin E, et al. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J. 2009;28:e271-e275.
60. Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121:253-260.
61. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics. 2009;124:e1-11.
62. Dunais B, Bruno-Bazureault P, Carsenti-Dellamonica H, et al. A decadelong surveillance of nasopharyngeal colonisation with Streptococcus pneumoniae among children attending day-care centres in south-eastern France: 1999-2008. Eur J Clin Microbiol Infect Dis. 2011;30:837-843.
63. Spijkerman J, van Gils EJ, Veenhoven RH, et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerging Infect Dis. 2011;17:584-591.
64. Vestrheim DF, Høiby EA, Aaberge IS, et al. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol. 2010;17:325-334.
65. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-1792.
66. Lacapa R, Bliss SJ, Larzelere-Hinton F, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis. 2008;47:476-484.
67. A new market to save lives from pneumococcal disease. Lancet Infect Dis. 2011;11:73.
68. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and effi cacy of a 9-valent conjugate pneumococcal vaccine in human immunodefi cient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25:2451-2457.
69. Tregnaghi M, Sáez-Llorens X, López P, et al. Evaluating the effi cacy of 10-valent pneumococcal non-typeable Haemophilus infl uenzae protein-d conjugate vaccine (PHiD-CV) against community-acquired pneumonia in Latin America. 29th Annual Meeting of the European Society for Paediatric Infectious Diseases. June 07-11, 2011; The Hague, the Netherlands.